Loading
PolyPeptide Group AG Stock: price and insider trades · Switzerland
No insider purchase over the last 90 days. The latest, by Anonymous (Non-executive member of the board of directors), was filed 09 Apr 2025.
PolyPeptide Group AG: what insiders have been doing
This page follows insider dealings at PolyPeptide Group AG as filed with SIX SER, a company from the Health Care sector based in Limhamn. The past year has been quiet: not a single insider filing for PolyPeptide Group AG. The previous disclosure was published on 9 April 2025.
These figures are compiled from regulatory filings published by SIX SER. They describe what insiders did and are not a recommendation.
Key facts
Headquarters: Limhamn
Source: Wikidata (CC0).
Insider Decl.
10
Thresholds
n/a
Buy Volume
€4M
10 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleAnonymous (Non-executive member of the board of directors)3 buys
Analyst consensus: bullish or bearish?
Analysts rate PolyPeptide Group AG Buy (bullish), based on 6 analysts. Average price target: CHF 38.81.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,828 of 24,166 companies
21.9
score / 100
Value19
Quality25
FCF yld-2.2%
Earn yld-1.5%
EV/EBITDA55.8x
ROE4.2%
Gross mgn17%
Net mgn-5.4%
Debt/EBITDA4.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CHF 43.95
Analyst consensus
6 analystsBuy
CHF 25.71Target CHF 38.81(-12%)CHF 45.29
Income statement
RevenueCHF 391.9M
Gross profitCHF 66.5M17% margin
EBITDACHF 28.3M7% margin
Net income-CHF 21.2M-5.4% margin
Valuation
PER (forward)28.4x
P/Book4.6x
Beta1.04
Balance sheet & cash
Market capCHF 1.5B
Total debtCHF 130.6M
Free Cash Flow-CHF 31.4M
Debt / Equity42%
Profitability & ownership
ROE-6.1%
ROA0.7%
% insiders60.5%
% institutions12.7%
Last declaration on 9 April 2025
Declarations10 total
1 shares@ CHF 50,000.0011.9% of flowISIN CH1110760852SIX:T1P49000B9
Canonical exit: 8 Jul 2025 (T+90)
1 shares@ CHF 75,000.0017.9% of flowISIN CH1110760852SIX:T1P49000D5
Canonical exit: 8 Jul 2025 (T+90)
1 shares@ CHF 72,000.0017.2% of flowISIN CH1110760852SIX:T1P49000C7
Canonical exit: 8 Jul 2025 (T+90)
1 shares@ CHF 72,000.0016.5% of flowISIN CH1110760852SIX:T1O4B00033
Canonical exit: 10 Jul 2024 (T+90)
1 shares@ CHF 75,000.0017.2% of flowISIN CH1110760852SIX:T1O4B00066
Canonical exit: 10 Jul 2024 (T+90)
1 shares@ CHF 50,000.0011.4% of flowISIN CH1110760852SIX:T1O4B00041
Canonical exit: 10 Jul 2024 (T+90)
1 shares@ CHF 35,000.008.0% of flowISIN CH1110760852SIX:T1O4B00058
Canonical exit: 10 Jul 2024 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
2,500 shares@ CHF 20.501.5% of flowISIN CH1110760852SIX:T1NBA00094
Canonical exit: 8 Feb 2024 (T+90)
159,959 shares@ CHF 17.981887.2% of flowISIN CH1110760852SIX:T1NAB00037
Canonical exit: 9 Jan 2024 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
22,041 shares@ CHF 16.841511.2% of flowISIN CH1110760852SIX:T1NAA00062
Canonical exit: 8 Jan 2024 (T+90)
10 of 10 declarations
About PolyPeptide Group AG
PolyPeptide Group AG is a company specializing in the development and manufacturing of peptides for the pharmaceutical and biopharmaceutical sectors. It is listed on the Swiss Exchange (XSWX).
